Lanreotide Zentiva (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors, primarily SSTR2 and SSTR5, on target cells. This binding blocks adenylate cyclase activity, lowers cAMP, and suppresses the release of growth hormone, insulin, glucagon, and other peptide hormones, thereby mitigating disease activity.

The specific dose and dosing interval of Lanreotide Zentiva are determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Healthcare professionals adjust the regimen according to clinical guidelines and patient needs.

Safety data for Lanreotide Zentiva in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Lanreotide is similar to other long‑acting somatostatin analogs such as octreotide, but it differs in formulation and dosing frequency. Both agents suppress hormone secretion, yet Lanreotide’s depot preparation may allow less frequent injections, offering convenience for some patients while maintaining comparable efficacy.

Lanreotide Zentiva should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods.

Lanreotide Zentiva is administered by subcutaneous injection. The injection is typically given into the abdomen or thigh using a pre‑filled syringe or autoinjector, following the technique and site‑rotation guidelines provided by the prescribing clinician.

Serious risks include the development of gallbladder disease (gallstones or cholecystitis), pancreatitis, severe hyperglycemia, and rare allergic reactions such as anaphylaxis. Patients should be monitored for abdominal pain, unexplained fever, or signs of hypersensitivity and seek medical attention promptly if they occur.

Lanreotide Zentiva is contraindicated in individuals with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for patients with uncontrolled diabetes, active gallbladder disease, or severe cardiac conduction abnormalities. The drug should be avoided in these populations unless a specialist determines that benefits outweigh risks.